[
    [
        {
            "time": "2021-02-25",
            "original_text": "网易全年净收入增长24%至737亿元 康希诺生物新冠疫苗附条件获批上市",
            "features": {
                "keywords": [
                    "网易",
                    "净收入增长",
                    "康希诺生物",
                    "新冠疫苗",
                    "附条件获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "科技",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "网易全年净收入增长24%至737亿元 康希诺生物新冠疫苗附条件获批上市",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-02-25",
            "original_text": "美的集团今日耗资3亿元回购320万股 这三家锂电池龙头又有大动作",
            "features": {
                "keywords": [
                    "美的集团",
                    "回购",
                    "锂电池",
                    "龙头"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "家电",
                    "新能源"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "美的集团今日耗资3亿元回购320万股 这三家锂电池龙头又有大动作",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-25",
            "original_text": "爱美客6天急跌26%！医美行业还值得看好吗？",
            "features": {
                "keywords": [
                    "爱美客",
                    "急跌",
                    "医美行业"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "爱美客6天急跌26%！医美行业还值得看好吗？",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-02-25",
            "original_text": "复星医药和BioNTech宣布mRNA新冠疫苗获澳门特别许可进口批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "mRNA新冠疫苗",
                    "澳门",
                    "进口批准"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药和BioNTech宣布mRNA新冠疫苗获澳门特别许可进口批准",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-25",
            "original_text": "复星医药：中国澳门向公司采购首批10.5万剂mRNA新冠疫苗BNT162b2",
            "features": {
                "keywords": [
                    "复星医药",
                    "澳门",
                    "mRNA新冠疫苗",
                    "采购"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：中国澳门向公司采购首批10.5万剂mRNA新冠疫苗BNT162b2",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-02-25",
            "original_text": "复星医药：澳门政府计划采购共计40万剂mRNA新冠疫苗BNT162b2",
            "features": {
                "keywords": [
                    "复星医药",
                    "澳门政府",
                    "采购",
                    "mRNA新冠疫苗"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：澳门政府计划采购共计40万剂mRNA新冠疫苗BNT162b2",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]